FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223642276> ?p ?o ?g. }

• W2223642276 endingPage "9024" @default.
• W2223642276 startingPage "9024" @default.
• W2223642276 abstract "9024 Background: IM is a highly effective treatment for metastatic/unresectable GIST. Although pts may exhibit durable systemic disease control, with time clonal evolution of lesions refractory to IM emerge and require alternative treatment approaches. We have evaluated the role of percutaneous RFA in this subset of pts with single or oligoclonal progressing GIST lesions who are in good performance status. Methods: Pts with limited sites of GIST progressing despite continuation of IM were treated with CT-guided RFA. All pts had staging with CT/MRI as well as functional imaging with 18FDG PET scans, both before and after RFA. Biopsy of the target lesions was performed before RFA. Results: Nine pts treated with imatinib for a median of 25 months (m) (range 18–36 m) underwent RFA for single or limited site(s) of progressing disease. Sites of progression: 8/9 pts with liver metastases, 1/9 with soft tissue disease. 5/9 of these pts developed a new nodule within a pre-existing GIST lesion, the remaining 4/9 had anatomic progression of pre-existing sites or developed a new site of disease. Pts undergoing the procedure were asymptomatic and had a good baseline performance status (ECOG 0–1). Progressing lesions were not 18FDG-avid by PET scanning in 5 pts. No pt developed early or late complications from the procedure. With median follow-up of 4.2 m (range 1–11 m), all pts had their lesions completely ablated. 5/9 pts progressed systemically and had an increase in their imatinib dosing (from 400 or 600mg/d to 800mg/d), resulting in disease control for an additional 1–6 m (median 3.5 m). 4 pts remain stable on continued treatment with imatinib (median follow-up 5.8 m). Conclusion: In this small cohort, percutaneous RFA appears to be a safe and effective treatment for localized sites of progression. This procedure helps to manage limited IM-resistant GIST. Continuation of IM to control systemic sites of IM-sensitive GIST despite emergence of limited clonal resistance can be justified on the basis of this exploratory work. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis; Pfizer Novartis; Pfizer" @default.
• W2223642276 created "2016-06-24" @default.
• W2223642276 creator A5023742645 @default.
• W2223642276 creator A5025908341 @default.
• W2223642276 creator A5030427075 @default.
• W2223642276 creator A5030483760 @default.
• W2223642276 creator A5042802176 @default.
• W2223642276 creator A5053434119 @default.
• W2223642276 creator A5060580923 @default.
• W2223642276 creator A5068151924 @default.
• W2223642276 creator A5082096953 @default.
• W2223642276 creator A5084954488 @default.
• W2223642276 date "2004-07-15" @default.
• W2223642276 modified "2023-10-15" @default.
• W2223642276 title "Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM)" @default.
• W2223642276 doi "https://doi.org/10.1200/jco.2004.22.90140.9024" @default.
• W2223642276 hasPublicationYear "2004" @default.
• W2223642276 type Work @default.
• W2223642276 sameAs 2223642276 @default.
• W2223642276 citedByCount "13" @default.
• W2223642276 countsByYear W22236422762013 @default.
• W2223642276 countsByYear W22236422762014 @default.
• W2223642276 countsByYear W22236422762022 @default.
• W2223642276 crossrefType "journal-article" @default.
• W2223642276 hasAuthorship W2223642276A5023742645 @default.
• W2223642276 hasAuthorship W2223642276A5025908341 @default.
• W2223642276 hasAuthorship W2223642276A5030427075 @default.
• W2223642276 hasAuthorship W2223642276A5030483760 @default.
• W2223642276 hasAuthorship W2223642276A5042802176 @default.
• W2223642276 hasAuthorship W2223642276A5053434119 @default.
• W2223642276 hasAuthorship W2223642276A5060580923 @default.
• W2223642276 hasAuthorship W2223642276A5068151924 @default.
• W2223642276 hasAuthorship W2223642276A5082096953 @default.
• W2223642276 hasAuthorship W2223642276A5084954488 @default.
• W2223642276 hasConcept C121332964 @default.
• W2223642276 hasConcept C121608353 @default.
• W2223642276 hasConcept C126322002 @default.
• W2223642276 hasConcept C126838900 @default.
• W2223642276 hasConcept C141071460 @default.
• W2223642276 hasConcept C142424586 @default.
• W2223642276 hasConcept C16930146 @default.
• W2223642276 hasConcept C2775922572 @default.
• W2223642276 hasConcept C2775934546 @default.
• W2223642276 hasConcept C2777007597 @default.
• W2223642276 hasConcept C2777377203 @default.
• W2223642276 hasConcept C2777583451 @default.
• W2223642276 hasConcept C2777910003 @default.
• W2223642276 hasConcept C2778729363 @default.
• W2223642276 hasConcept C2778902805 @default.
• W2223642276 hasConcept C2779490328 @default.
• W2223642276 hasConcept C2780400711 @default.
• W2223642276 hasConcept C2780813298 @default.
• W2223642276 hasConcept C2781464078 @default.
• W2223642276 hasConcept C3019892230 @default.
• W2223642276 hasConcept C500558357 @default.
• W2223642276 hasConcept C71924100 @default.
• W2223642276 hasConcept C87355193 @default.
• W2223642276 hasConceptScore W2223642276C121332964 @default.
• W2223642276 hasConceptScore W2223642276C121608353 @default.
• W2223642276 hasConceptScore W2223642276C126322002 @default.
• W2223642276 hasConceptScore W2223642276C126838900 @default.
• W2223642276 hasConceptScore W2223642276C141071460 @default.
• W2223642276 hasConceptScore W2223642276C142424586 @default.
• W2223642276 hasConceptScore W2223642276C16930146 @default.
• W2223642276 hasConceptScore W2223642276C2775922572 @default.
• W2223642276 hasConceptScore W2223642276C2775934546 @default.
• W2223642276 hasConceptScore W2223642276C2777007597 @default.
• W2223642276 hasConceptScore W2223642276C2777377203 @default.
• W2223642276 hasConceptScore W2223642276C2777583451 @default.
• W2223642276 hasConceptScore W2223642276C2777910003 @default.
• W2223642276 hasConceptScore W2223642276C2778729363 @default.
• W2223642276 hasConceptScore W2223642276C2778902805 @default.
• W2223642276 hasConceptScore W2223642276C2779490328 @default.
• W2223642276 hasConceptScore W2223642276C2780400711 @default.
• W2223642276 hasConceptScore W2223642276C2780813298 @default.
• W2223642276 hasConceptScore W2223642276C2781464078 @default.
• W2223642276 hasConceptScore W2223642276C3019892230 @default.
• W2223642276 hasConceptScore W2223642276C500558357 @default.
• W2223642276 hasConceptScore W2223642276C71924100 @default.
• W2223642276 hasConceptScore W2223642276C87355193 @default.
• W2223642276 hasIssue "14_suppl" @default.
• W2223642276 hasLocation W22236422761 @default.
• W2223642276 hasOpenAccess W2223642276 @default.
• W2223642276 hasPrimaryLocation W22236422761 @default.
• W2223642276 hasRelatedWork W1968311207 @default.
• W2223642276 hasRelatedWork W2123425136 @default.
• W2223642276 hasRelatedWork W2363948415 @default.
• W2223642276 hasRelatedWork W2395519504 @default.
• W2223642276 hasRelatedWork W2397935960 @default.
• W2223642276 hasRelatedWork W2771867163 @default.
• W2223642276 hasRelatedWork W2922742752 @default.
• W2223642276 hasRelatedWork W2993446785 @default.
• W2223642276 hasRelatedWork W4285190342 @default.
• W2223642276 hasRelatedWork W2548298627 @default.
• W2223642276 hasVolume "22" @default.
• W2223642276 isParatext "false" @default.
• W2223642276 isRetracted "false" @default.
• W2223642276 magId "2223642276" @default.

• next